Triton, Carlyle weigh bids for Germany's REMA Tip Top, sources say
By Emma-Victoria Farr and Andres Gonzalez
FRANKFURT (Reuters) -Private equity funds, including Carlyle and Triton, are weighing bids for Germany-based industrial equipment maker REMA Tip Top, which is exploring a possible sale, three people familiar with the matter said.
The family-owned maker of industrial conveyor belts is working with an adviser to explore its options, which include a sale, the sources said. The stake size on offer has not yet been decided, two of the sources said.
The firm generated 1.4 billion euros of revenue in 2023, according to the company, putting its possible value north of 3 billion euros in any deal, for which formal talks could start after August, one of the sources said.
The owners are considering bringing on external investors to grow the business, the person said.
The sources spoke on condition of anonymity because the matter is private.
Carlyle and Triton declined to comment. REMA Tip Top did not immediately return requests for comment.
A sale would come amid a muted time for dealmaking after the revelation of U.S. tariffs in April put a halt on transactions.
Germany's economy, heavily dependant on exporting to an increasingly volatile world, has been stagnating for years. A government borrowing splurge is in the works but it remains unclear whether that will help.
The firm would be the latest family-owned company to come up for sale as a wave of business owners in Germany's so-called Mittelstand look to exit without successors.
REMA was founded in 1923 by brothers Otto and Willy Gruber as part of the Stahlgruber Group, concentrating on providing basic materials and tools for industry and trade in the 1920s as a supplier in the German industrial landscape.
The firm focuses on sustainable services in the field of conveyor and processing systems as well as tyre repair. Its business services are used in areas including the automotive industry, chemicals, energy, water treatment and pulp and paper.
REMA Tip Top has more than 9,000 employees and 200 subsidiaries worldwide, it says on its website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Ex-Blackstone Investor Raises $7M for Meridian, Private Equity's New AI Operating System
NEW YORK, June 20, 2025--(BUSINESS WIRE)--Meridian, the AI-powered deal management platform for the private markets, today announced its $7 million Series Seed fundraise. The round was led by 645 Ventures with participation from existing investor Chaac Ventures. Meridian also welcomed a group of high-impact angel investors – industry leaders from private equity, credit, and M&A law, many of whom have actively shaped Meridian as early users. Founded by Alexander Sen, a former investor at Blackstone, Thoma Bravo, and CVC, Meridian is building the AI operating system for private market investors. The company combines modern CRM with deep workflow automation and proprietary AI agents to solve the core operational pain points of the world's leading investors – from deal origination to exit. "Private equity still runs on fragmented, manual systems: clunky software, Excel trackers, and scattered third-party data subscriptions," said Alexander Sen, founder and CEO of Meridian. "We're building software that finally reflects how top investment teams source and diligence deals – and we've vertically integrated AI to enable workflows that were never possible before." Meridian brings together a team of over 25 across New York and Miami, with experience spanning enterprise software, AI infrastructure, and capital markets. The company has also hired an experienced customer team who guide firms through the most important technological shift facing private markets today. At the heart of the platform is Scout, Meridian's AI engine. Scout powers intelligent agents that map markets, pinpoint the right companies, automate core evaluation workflows, and surface relationship signals where they matter most. It helps firms spot high-conviction deals before the market does – giving teams a decisive sourcing and diligence edge. Meridian has to date focused on the top of the market, helping some of the world's largest private equity and credit firms run better, more intelligent deal sourcing and evaluation processes. The platform is quickly gaining share at top 100 firms and is now expanding into LPs, investment banks, and global hedge funds – reflecting a broader shift toward modern infrastructure across every layer of private company investing. "There's a generational shift happening in private markets – more complexity, more competition, and more data," said Nnamdi Okike, Managing Partner at 645 Ventures. "AI is a game changer for private market deal sourcing, due diligence and deal management. Firms that do not leverage AI in this new market will be left behind. We were particularly drawn to Alex's insights into how AI will transform private markets, which were developed through his experience in private equity. Meridian is arming investors with the system they'll need to win." The funding will be used to expand Meridian's AI capabilities, accelerate product development, and scale go-to-market efforts globally. "Private market firms are under pressure to move faster, operate leaner, and make sharper decisions," said Sen. "Software is no longer just overhead at private equity firms – it's become a source of edge. The best investors are treating technology and data as central to how they generate outsized returns." To request a demo or learn more, visit About Meridian Meridian is the AI-native operating system for institutional private markets. The platform combines next-generation deal software, massive datasets, and intelligent agents into a single system that helps investors originate, evaluate, and execute with greater speed and precision. Founded by Alexander Sen, a former investor at Blackstone, Thoma Bravo, and CVC, Meridian serves private equity, credit, and broader financial services firms engaged in M&A. The company is headquartered in New York and Miami, with a team of product builders, engineers, and customer leaders with deep experience across enterprise software and private markets. Learn more at About 645 Ventures 645 Ventures is an early-stage venture capital firm that partners with exceptional founders building iconic companies. The firm invests at the Seed and Series A stages and supports founders through its proprietary software platform Voyager and deep Connected Network. 645 Ventures manages over $550M in AUM across five funds. Learn more at View source version on Contacts Media Contact Kelsey Cullen, KCPR650.438.1063kelsey@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Global Economic Outlook: US, Europe Grow More Slowly Than Expected Amid Trade, Geopolitical Tensions
Scope Ratings (Scope) has revised its forecast for US growth to 1.8% this year from a previous forecast of 2.7% last October (Table 1), while forecasting growth of 1.8% in 2026. US output rose 2.8% last year. The European rating agency's forecast is for global growth to slow to 3.0% in 2025 from 3.3% in 2024 before continuing at a moderate rate of 3.1% next year. Download Scope Ratings' mid-year 2025 Economic Outlook. Medium-term macro risks remain negatively skewed. Scope projects that interest rates will remain above the pre-pandemic levels amid structurally higher inflation. The cut to US growth forecasts for this year comes amid trade uncertainties and cuts in government spending by the Department of Government Efficiency. As regards Germany, Scope forecasts no growth this year compared with a forecast last October of 0.9% – the economy contracted 0.2% in 2024 – but sees output in Europe's largest economy expanding by 1.2% next year. Germany's sluggish performance this year will drag euro-area growth to a less-than-expected 1.1%, 0.5pps below Scope Ratings' former forecast, before a slight rebound in 2026 to 1.5%. Spain and economies of the euro-area periphery – such as Greece, Ireland, Portugal – continue to outperform the rest of the euro area. Spain's forecast growth this year of 2.5%, revised up by 0.3pps, contrasts with France's of 0.7%, cut 0.6pps, and Italy's of 0.6%, revised down by 0.4pps. Table 1: Scope Ratings' growth forecasts, summary %, projections as of 20 June 2025 Scope expects stronger growth in Europe in 2026 as defence spending rises and governments implement measures to increase investment. Looking ahead, Scope sees four adverse factors weighing on the outlook for the global economy and global credit. First, there are the on-again, off-again escalations and de-escalations of trade tensions posing recessionary risks for the global economy. Secondly, threats are increasing for financial stability amplified by the latest wave of financial deregulation spear headed by the United States. Another factor is the budgetary challenges that governments face, triggering more frequent market re-appraisals of sovereign debt risks. Finally, there are heightened geopolitical risks, not least Russia's continuing war in Ukraine and the recent escalation of conflict between Israel and Iran. The rating agency assumes higher steady-state borrowing rates than the rates that prevailed before the cost-of-living crisis. Many central banks have paused rate reductions, even if the Federal Reserve and Bank of England may resume them later this year whereas the Bank of Japan is gradually increasing rates. Sustained higher borrowing rates and elevated financial-market valuations amid financial deregulation threaten corrections and present risks for financial stability and global credit conditions. Presentation: Scope's 2025 mid-year economic and credit outlook Data: Scope's mid-year 2025 economic projections For a look at all of today's economic events, check out our economic calendar. Dennis Shen is the Chair of the Macro Economic Council and Lead Global Economist of Scope Group. The rating agency's Macroeconomic Council brings together the company's credit opinions from multiple issuer classes: sovereign and public sector, financial institutions, corporates, structured finance and project finance. This article was originally posted on FX Empire From Tariffs to Tags: The Price Hike Reality for US Shoppers (Part 1) Bulgaria Poised to Join the Euro: An Interview with Scope Ratings' Dennis Shen Big Money Lifts Disney 1,427% Since First Outlier Buy Royal Caribbean Seeing Inflows Ulta Beauty Sales Growth Attracts Inflows Rare Bullish Inflow Signals Cause IMAX to Nearly Double
Yahoo
3 hours ago
- Yahoo
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
